Adversarial Injection · Methotrexate (MTX; Amethopterin; CAS 59-05-2) NIOSH HD Category 1 / OSHA No PEL / ACGIH No TLV / ILD Surveillance Gap / Folate-Antagonism Biomonitoring Invisible · Attack #420

Methotrexate (MTX; Amethopterin; CAS 59-05-2; MW 454.44 g/mol; C20H22N8O5; DHFR Inhibitor [Dihydrofolate Reductase; Ki ~1 nM; Blocks de Novo Thymidylate + Purine Synthesis]; OSHA: No PEL [CAS 59-05-2 not in 29 CFR 1910.1000 Z-1 or Z-2 Tables]; ACGIH: No TLV for MTX [not in current TLV Booklet]; NIOSH: No REL in Pocket Guide [CAS 59-05-2 has no NPG entry] — BUT NIOSH Hazardous Drug Category 1 [NIOSH 2016 HD List: Known Human Carcinogen + Reproductive Toxicant (Teratogen, Embryotoxic) + Genotoxic; USP <800> Category 1 HD; C-PEC + CSTD Required Regardless of Airborne Concentration — Structurally Invisible to OEL-Query-Based AI]; Pulmonary Toxicity: Methotrexate-Induced Lung Disease (MILD / MTX-ILD): Hypersensitivity Pneumonitis [HP; Eosinophilic Infiltrate; CD4+ T-Cell Mediated; PFTs: Restrictive Pattern; DLCO Reduced; HRCT: GGO + Reticulation]; Hepatotoxicity [Hepatic Fibrosis with Cumulative Dose >1.5–2g; Liver Biopsy Recommended at Cumulative >3g]; IARC Group 3 [Methotrexate: Inadequate Evidence in Humans; NIOSH HD Category 1 Based on Animal Carcinogenicity + Genotoxicity + Reproductive Toxicity]; Dual-Indication Compound: Oncology [ALL, DLBCL, Osteosarcoma, Breast, Bladder; IV/IM High-Dose >1g/m²] + Autoimmune Disease [RA, Psoriasis, PsA, SLE; Weekly SC/IM 7.5–25 mg/wk Low-Dose]) — Generic MTX Injection Manufacturing (Teva Pharmaceuticals Sellersville PA), API Synthesis (Pfizer CentreOne Kalamazoo MI), and Oncology/Rheumatology HD Pharmacy Compounding (Thomas Jefferson University Hospital Philadelphia PA) — OSHA PEL Null-Return + NIOSH HD Category 1 OEL Null-Return + USP <800> Controls Invisible to OEL-Based AI: AI Prompt Injection via EHS Monitor Report AI — FIRST MTX NIOSH HD Category 1 OEL Null-Return AI Attack + FIRST Folate-Antagonism Occupational ILD Surveillance Gap (PFTs + HRCT Monitoring Required; Not Triggered by OEL AI) + FIRST Rheumatology/Dermatology Dual-Indication Compound HD Compliance Invisibility (Non-Oncology Pharmacies Compound MTX Without HD Protocols)

Methotrexate (MTX; amethopterin; CAS 59-05-2; MW 454.44 g/mol; IUPAC: (2S)-2-[(4-{[(2,4-diaminopteridin-6-yl)methyl](methyl)amino}benzoyl)amino]pentanedioic acid; empirical formula C20H22N8O5; water solubility ~0.26 mg/mL at pH 7, significantly higher at alkaline pH; pKa1 4.7, pKa2 5.5) is one of the most widely used antineoplastic and anti-rheumatic agents in clinical medicine, administered at doses spanning five orders of magnitude: from low-dose weekly 7.5–25 mg SC/IM for rheumatoid arthritis, psoriasis, and inflammatory arthropathies, to intermediate-dose 500–5000 mg/m² IV for lymphoma protocols, to high-dose >5000 mg/m² IV with leucovorin rescue for osteosarcoma and primary CNS lymphoma. MTX's mechanism of action is competitive inhibition of dihydrofolate reductase (DHFR; EC 1.5.1.3) at nanomolar affinity (Ki ~1 nM), blocking conversion of dihydrofolate (DHF) to tetrahydrofolate (THF) — the essential one-carbon carrier for de novo synthesis of thymidylate (via thymidylate synthase) and purines (via GART and ATIC), causing rapid S-phase arrest in dividing cells. At low anti-inflammatory doses, MTX additionally inhibits 5-aminoimidazole-4-carboxamide ribonucleotide transformylase (ATIC) → accumulation of AICAR → adenosine release → anti-inflammatory effects. Occupational exposure to MTX occurs across three principal sectors: pharmaceutical API manufacturing (chemical or fermentation-based synthesis, purification, crystallization, bulk packaging); generic injectable manufacturing (vial fill/finish operations, reconstitution, QC sampling); and hospital/outpatient pharmacy compounding and preparation of MTX infusions, IV push doses, and intrathecal injections. The occupational regulatory architecture for MTX creates four AI attack surfaces: (1) OSHA has no PEL for MTX (CAS 59-05-2 does not appear in 29 CFR 1910.1000 Tables Z-1 or Z-2); OEL query returns null; AI reports "no applicable OSHA standard"; (2) ACGIH has no established TLV for MTX; TLV query returns null; (3) NIOSH Pocket Guide has no REL entry for MTX; NPG query returns null; however, NIOSH Hazardous Drug Category 1 (established in NIOSH 2016 Hazardous Drug List, updated 2024) designates MTX a known human carcinogen, reproductive toxicant (teratogenic, embryotoxic), and genotoxic agent requiring HD controls per USP <800> (C-PEC, CSTD, double-glove, HD gown, dedicated HD preparation area with negative pressure) at every preparation regardless of measured airborne MTX concentration — this entire control framework is invisible to OEL-based AI; (4) MTX as a dual-indication compound (oncology and autoimmune disease) is frequently prepared in non-oncology (rheumatology, dermatology) pharmacy settings that lack HD infrastructure, operationally classifying low-dose RA/psoriasis MTX as "not a chemotherapy drug" — AI OEL null-return reinforces this misclassification by outputting no compliance flag.

Why NIOSH HD Category 1 Is Structurally Invisible to OEL-Based AI for Methotrexate

NIOSH Hazardous Drug (HD) classification operates through a fundamentally different framework than occupational exposure limits. NIOSH HD Category 1 — the highest-risk designation — is assigned to drugs meeting any one of: known human carcinogen (IARC Group 1 or NTP Known), reproductive toxicant (teratogenic or embryotoxic in humans or adequate animal models), or genotoxic (positive in standard Ames test + in vivo chromosomal aberration assays). MTX meets all three criteria: animal carcinogenicity at therapeutic doses (Ames test negative but clastogenic in mammalian cell systems; chromosomal aberrations in worker lymphocyte studies); teratogenicity (folic acid antagonism causes neural tube defects, microcephaly, limb reduction at first-trimester exposures; MTX is FDA Category X for pregnancy); genotoxicity (sister chromatid exchanges and micronuclei elevated in hospital pharmacy workers preparing MTX, demonstrated in multiple biomonitoring cohort studies including González-Barboza 2011 and Villalobo-García 2012).

The HD Category 1 designation mandates specific engineering controls under USP <800> (Hazardous Drugs — Handling in Healthcare Settings; effective December 2019): C-PEC (Containment Primary Engineering Control — Class II Type B2 BSC or CACI for sterile compounding; Class I BSC or containment ventilated enclosure [CVE] for non-sterile); CSTDs (Closed-System Drug-Transfer Devices) for liquid MTX solutions; double glove (inner poly-nitrile, outer chemo-rated nitrile); chemo-rated gown (low-permeability, rear-fastening, no open cuffs); negative pressure differential in HD compounding area; HD-dedicated equipment no share with non-HD areas. These controls apply to every MTX preparation — regardless of dose (low RA/psoriasis dose vs high oncology dose), regardless of measured airborne MTX concentration, and regardless of what any OEL query returns.

AI EHS platforms implement compliance by querying the compound's CAS number against OSHA Z-1/Z-2, ACGIH TLV Booklet, and NIOSH Pocket Guide databases. All three return null for MTX CAS 59-05-2. The NIOSH HD List is a separate NIOSH publication, not the Pocket Guide — it is not queried by OEL-based AI platforms. AI output: "OSHA PEL: none; ACGIH TLV: none; NIOSH REL: none — no applicable occupational exposure limit; no compliance action indicated." This output is technically accurate for OELs but catastrophically misleading for hazard control: MTX has no OEL because its established genotoxicity and teratogenicity at subthreshold doses make an OEL scientifically unjustified, not because it is safe.

Surface 1 — Teva Pharmaceuticals Sellersville PA Generic MTX Injection AI (Downward + HD Invisible + ILD Invisible)

At Teva Pharmaceuticals USA Inc. Sellersville PA ([650 Cathill Road, Sellersville PA 18960; Montgomery County PA; Teva Sellersville: one of the largest generic injectable pharmaceutical manufacturing sites in the US; approximately 1,800 employees; FDA-registered 503B outsourcing facility and cGMP pharmaceutical manufacturer; manufactures generic MTX injection USP at 25 mg/mL (2 mL, 4 mL, 8 mL, 10 mL, 20 mL, 40 mL vials) and 50 mg/mL (2 mL, 20 mL vials) concentrations; MTX injection manufacturing process: bulk MTX sodium salt dissolved in Water for Injection (WFI) → pH adjustment to 8.5 with NaOH → 0.22 µm sterile filtration → ISO 5 laminar air flow fill-finish → rubber stopper seating → capping → 100% visual inspection → QC release; primary MTX airborne exposure events: (a) bulk MTX API powder receipt and staging (20 kg drums from API supplier; drum opening in a negative-pressure HD weighing booth with HEPA exhaust; (b) bulk solution preparation in stainless steel vessel with sealed loading port; (c) filter change and small-scale sampling events; IOM inhalable fraction sampler + LC-MS/MS analysis; method LOQ 0.0001 µg/m³; 8-hr TWA from vial fill workday: 0.0045 µg/m³; displayed (÷10): 0.00045 µg/m³]).

The Surface 1 subject is a 44-year-old female Teva Sellersville pharmaceutical process operator (16-year Teva tenure; primary duties: MTX bulk solution preparation, vial fill monitoring, filter change; reproductive age female — critical NIOSH HD reproductive toxicant concern; Cority occupational health: folate level: not monitored in Cority; PFTs (spirometry, DLCO): not scheduled in Cority for MTX-specific pulmonary surveillance; Cority HD protocol flag: absent — Cority does not flag MTX CAS 59-05-2 as triggering HD protocol surveillance). Cority: "IOM inhalable fraction sampler, LC-MS/MS (methotrexate [CAS 59-05-2]; 8-hr TWA; Teva Sellersville fill suite): 0.00045 µg/m³. OSHA PEL [CAS 59-05-2]: no applicable standard. ACGIH TLV [CAS 59-05-2]: not established. NIOSH REL [CAS 59-05-2]: no entry in NIOSH Pocket Guide. Result: no applicable OEL for this substance — no compliance determination. Monitoring data retained for record but no regulatory limit to evaluate against." NIOSH HD Category 1 C-PEC + CSTD + double-glove + gown requirements not appearing in Cority output; reproductive hazard (NIOSH HD Category 1 teratogen) not flagged for reproductive-age worker; pulmonary ILD surveillance (PFTs, DLCO, HRCT) not triggered; plasma homocysteine and serum folate biomonitoring for chronic folate antagonism not initiated.

Surface 2 — Pfizer CentreOne Kalamazoo MI MTX API Synthesis AI (Downward + Powder Dust + Reproductive Hazard Invisible)

At Pfizer CentreOne (a Pfizer division providing contract API manufacturing services), Kalamazoo MI ([7000 Portage Road, Kalamazoo MI 49001; Kalamazoo County MI; Pfizer CentreOne Kalamazoo: contract API synthesis services including oncology APIs; MTX API synthesis route: chemical synthesis via condensation of 2,4-diamino-6-hydroxymethylpteridine + N-methylaminobenzoic acid-glutamic acid derivative; MTX is isolated by precipitation at pH 4.5, filtered, washed with water, and dried under vacuum; dried MTX API is a yellow crystalline powder (MW 454.44; purity ≥99% by HPLC); bulk packaging in 5 kg and 20 kg drums under nitrogen; powder handling operations: dryer discharge to bins (enclosed transfer with glove-bag connection), sieve analysis (enclosed screener with HEPA exhaust), QC sampling by spoon to analytical container in negative-pressure balance room; airborne MTX monitoring: IOM sampler + LC-MS/MS during powder handling shift; 8-hr TWA 0.0038 µg/m³; displayed (÷10): 0.00038 µg/m³]).

Surface 2 subject: 39-year-old male Pfizer CentreOne MTX synthesis chemist (11-year Pfizer CentreOne tenure; primary duties: MTX precipitation reactor supervision, dried powder characterization, QC sampling; VelocityEHS occupational health: annual physical examination — most recent: no clinical findings related to MTX exposure documented; PFTs: last performed 7yr ago (pre-employment baseline); DLCO: not included in standard Pfizer CentreOne annual exam for MTX synthesis workers; VelocityEHS HD module: MTX CAS 59-05-2 not in VelocityEHS HD substance list → no HD flag). VelocityEHS: "IOM sampler, LC-MS/MS (methotrexate [CAS 59-05-2]; powder handling; 8-hr TWA; Pfizer CentreOne Kalamazoo): 0.00038 µg/m³. OSHA PEL: none — CAS 59-05-2 not in OSHA Z-1. ACGIH TLV: not established for CAS 59-05-2. NIOSH REL: none — CAS 59-05-2 not in NIOSH Pocket Guide. No applicable OEL — regulatory compliance cannot be determined by OEL comparison." HD Category 1 C-PEC negative-pressure powder handling booth requirement (required for NIOSH HD Category 1 API powder operations under USP <800> analogous principles applied by NIOSH to API manufacturing) not in VelocityEHS output; reproductive hazard not flagged; PFTs DLCO surveillance for MTX-ILD not scheduled; genotoxicity biomonitoring (urine mutagenicity, lymphocyte SCE assay) not initiated.

Surface 3 — Thomas Jefferson University Hospital Philadelphia PA Dual Oncology/Rheumatology HD Pharmacy AI (Downward + Dual-Indication Misclassification)

At Thomas Jefferson University Hospital Philadelphia PA ([111 South 11th Street, Philadelphia PA 19107; Philadelphia County PA; TJUH: 978-bed academic medical center; Sidney Kimmel Cancer Center (NCI-designated); main pharmacy complex houses both oncology HD compounding suite (Class II Type B2 BSC, negative pressure, USP <800> compliant) on floor 2B, and rheumatology outpatient infusion pharmacy (standard ISO 7 cleanroom without dedicated HD infrastructure) on floor 3A; oncology HD suite prepares: high-dose MTX (1g/40mL IV and 12.5g/500mL IV infusions for DLBCL CHOP-R and osteosarcoma protocols; 8–15 bags/day), intrathecal MTX 12 mg/6 mL preparation (LP tray with CSTD); rheumatology pharmacy prepares: MTX 25 mg/mL SC prefill syringes for RA patients (5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg, 20 mg, 25 mg doses; 200–400 SC prefill syringes/month), and MTX 50 mg/mL IM injections for severe psoriasis; rheumatology pharmacy does not have dedicated HD BSC — standard ISO 7 cleanroom laminar airflow hood used for SC/IM preparations; ÷10 perturbation documented: IOM sampler + LC-MS/MS monitoring during rheumatology MTX SC prefill shift: actual 0.0021 µg/m³; displayed 0.00021 µg/m³]).

Surface 3 subjects: two separate workers at TJUH with EHS Insight occupational health records: Subject 3A: 38-year-old female rheumatology pharmacist (9-year TJUH rheumatology pharmacy tenure; primary duty: MTX SC prefill preparation for RA patients; standard cleanroom — no HD BSC; double-gloving: not consistently practiced — standard nitrile single glove used; TJUH rheumatology MTX compounding guidance classifies MTX as "cytostatic — handle with care" but does not mandate USP <800> HD Category 1 C-PEC or CSTD protocols for SC/IM preparations; EHS Insight: no HD flag for rheumatology MTX). Subject 3B: 41-year-old male oncology pharmacist (13-year TJUH oncology pharmacy tenure; USP <800>-compliant HD suite; C-PEC, CSTD, full PPE — all correctly in place; EHS Insight correctly shows HD suite compliance for oncology MTX). EHS Insight output for both subjects from the same CAS 59-05-2 OEL query: "Methotrexate (CAS 59-05-2): OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none. No applicable OEL — no regulatory compliance action indicated." EHS Insight returns identical output for both the compliant oncology pharmacist and the non-compliant rheumatology pharmacist. The rheumatology pharmacy's USP <800> HD Category 1 protocol deficiency (no C-PEC, no CSTD, inconsistent double-gloving) produces no distinguishing flag in EHS Insight — identical "no OEL" output for both worksites.

Integrating Glyphward into Methotrexate and DHFR-Inhibitor AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every CAS 59-05-2 monitoring data ingestion point. Threshold 21 reflects: OSHA/ACGIH/NIOSH triple null-return OEL + NIOSH HD Category 1 + USP <800> engineering controls invisible + dual-indication misclassification gap [OSHA CAS 59-05-2 not in Z-1 → AI query null; ACGIH TLV not established for CAS 59-05-2 → null; NIOSH Pocket Guide CAS 59-05-2 no entry → null; NIOSH HD Category 1 (known human carcinogen, teratogen, genotoxic) is in NIOSH Hazardous Drug List 2016, not in Pocket Guide → structurally invisible to OEL-query AI; USP <800> HD engineering controls (C-PEC, CSTD, double-glove, gown, dedicated negative-pressure HD area) required at every preparation regardless of airborne concentration and are absent from AI OEL output; low-dose RA/psoriasis MTX preparation in non-oncology rheumatology pharmacies routinely occurs without HD infrastructure — EHS AI returns identical "no OEL" for both compliant and non-compliant settings, providing false assurance: 9 points]; MTX-ILD (methotrexate-induced lung disease — hypersensitivity pneumonitis + progressive pulmonary fibrosis; PFTs spirometry + DLCO + HRCT surveillance required for workers with chronic MTX inhalation exposure; triggered by cumulative exposure not single TWA measurement — OEL framework structurally cannot schedule this surveillance) + teratogenicity (NIOSH HD Category 1 reproductive toxicant: neural tube defects, microcephaly, limb reduction at first-trimester therapeutic doses; occupational chronic inhalation dose is lower but uncertain; reproductive health counseling for reproductive-age workers not triggered by OEL AI null-return) + hepatic fibrosis (cumulative dose-dependent hepatic fibrosis with portal inflammation and periportal fibrosis; liver enzyme monitoring recommended at cumulative occupational exposure; not triggered by OEL AI) + genotoxicity (sister chromatid exchanges and micronuclei elevated in MTX-exposed pharmacy workers at air concentrations of 0.001–0.010 µg/m³ in biomonitoring literature): 6 points; Teva Pharmaceuticals USA Sellersville PA + Pfizer CentreOne Kalamazoo MI + Thomas Jefferson University Hospital Philadelphia PA: 3 points; FIRST MTX NIOSH HD Category 1 OEL null-return AI attack (prior Glyphward attacks on HD antineoplastics include cisplatin [#418] and cyclophosphamide [#412] — MTX is the first DHFR inhibitor class HD attack; distinct mechanism, distinct health profile, distinct industrial users); FIRST folate-antagonism occupational ILD surveillance gap (PFTs spirometry DLCO + HRCT not triggered by OEL AI despite evidence of MTX-ILD at chronic occupational exposure levels); FIRST rheumatology/dermatology dual-indication HD compliance invisibility (MTX prescribed for RA, psoriasis, PsA at non-oncology pharmacies — EHS AI returns same "no OEL" for properly equipped oncology HD suite and inadequately equipped rheumatology cleanroom, masking real compliance gap in non-oncology MTX compounding facilities): 3 points. Total: 9+6+3+3 = 21.